FIELD: biotechnology.
SUBSTANCE: disclosed is a composition for preparing a medicament for treating disorders or diseases associated with B-cells, comprising an isomerised version of the anti-BCMA antibody, where composition contains 0.1–25% of the isomerised version of isoaspartate at position 103 in the CDRH3 of the heavy chain based on the total amount of 100% of the antibody in the composition. Also disclosed are a pharmaceutical composition for treating disorders or diseases associated with B-cells and a pharmaceutical composition for treating disorders or diseases associated with B-cells, containing the pharmaceutical composition.
EFFECT: invention is used to treat diseases or disorders mediated by BCMA.
15 cl, 4 dwg, 35 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ANTI-ApoC3 ANTIBODIES AND METHODS FOR THEIR USE | 2018 |
|
RU2781074C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| BIOLOGICAL MATERIALS AND THEIR APPLICATION METHODS | 2011 |
|
RU2769949C2 |
| HUMAN TLR7 ANTIBODY | 2019 |
|
RU2808123C2 |
| ANTI-ORAI1 ANTIBODY | 2015 |
|
RU2724742C2 |
